• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis reports first NEATstik® sale
Share
NEATstik Airways Test
NEATstik®

ProAxsis reports first NEATstik® sale

February 15, 2018
-
Posted by David Ribeiro

Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel sputum-based point-of-care test, to a research laboratory conducting an ongoing respiratory clinical trial for a pharmaceutical company. NEATstik® was registered with a CE Mark in the second half of 2017 and utilises the company’s proprietary ProteaseTag® technology to allow the rapid, qualitative measurement of the active form of neutrophil elastase, an established biomarker of lung infection and inflammation.

Dr David Ribeiro, CEO of ProAxsis, commented: “The first sale of our innovative point-of-care test, NEATstik®, is another notable milestone for the company, as we expand our portfolio of commercialised products. This, combined with a strong sales performance for the company’s ProteaseTag® Active Neutrophil Elastase Immunoassay in January, represents a very positive start to the year for the company’s commercial aspirations in 2018.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

February 15, 2018

Related News

Other posts that you should not miss.
Conferences, NEATstik®

ProAxsis presenting new data at 2018 European Respiratory Society Conference

September 18, 2018
-
Posted by David Ribeiro

ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, …

Read More
September 18, 2018
Posted by David Ribeiro
Announcements, NEATstik®, News

New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases

June 3, 2019
-
Posted by Webmaster

Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the …

Read More
June 3, 2019
Posted by Webmaster
Conferences, NEATstik®

ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting

December 5, 2017
-
Posted by Webmaster

ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes …

Read More
December 5, 2017
Posted by Webmaster
← PREVIOUS POST
New opportunity for Early Stage Researcher at Queen’s University Belfast
NEXT POST →
ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis reports first NEATstik® sale - ProAxsis